History

HCG is a long-approved prescription drug, with original urinary products dating to the mid-20th century. Pharmaceutical hCG (e.g., Pregnyl, Novarel) is purified from the urine of pregnant women, and a recombinant form, choriogonadotropin alfa (Ovidrel), is produced in cell culture for assisted reproduction. Its FDA-labeled indications are prepubertal cryptorchidism not due to anatomical obstruction, selected cases of secondary (pituitary-origin) hypogonadotropic hypogonadism in males, and induction of ovulation in appropriately selected anovulatory infertile women. A separate weight-loss use — the "hCG diet" attributed to Simeons' 1954 protocol — was never approved and is explicitly disclaimed on the label.

HCG is one of the most misunderstood compounds in the fitness and weight-loss worlds, largely because it is constantly described as if it were a steroid or a “peptide” performance drug. It is neither in the sense people assume: it is a glycoprotein hormone — a gonadotropin — that works by mimicking luteinizing hormone and telling the gonads to make more of their own sex steroids. That distinction drives everything about how it works, what it is actually good for, and where the marketing around it goes wrong.

What it is

HCG is a glycoprotein hormone, not a steroid. The familiar steroid descriptors — “androgen receptor agonist,” “17-alpha-alkylated oral,” “injectable ester” — do not apply to it; those belong to anabolic-androgenic steroids (AAS). HCG has no alkylated oral form and no ester chemistry. It is a glycoprotein given by injection (intramuscular or subcutaneous) because it would be digested if taken orally.

Structurally it is a heterodimer of two non-covalently linked subunits: an alpha subunit (identical to the alpha subunit shared by LH, FSH, and TSH) and a beta subunit unique to hCG that confers its biological specificity. The hCG beta subunit closely resembles the LH beta subunit but carries an additional C-terminal extension (a roughly 30-residue carboxy-terminal peptide). The molecule totals about 237 amino acids and is heavily glycosylated (~36–37 kDa). In chemical structure it is a peptide/glycoprotein hormone — but it is not an anabolic steroid, and it is not the kind of small “research peptide” it is often lumped in with.

Mechanistically, hCG acts as an LH analog (a luteinizing-hormone mimetic). It binds the shared LH/CG receptor (LHCGR), a Gs-coupled GPCR found on Leydig cells in the testes and theca/granulosa cells in the ovary. Receptor activation raises cAMP, then activates PKA, upregulating StAR protein and steroidogenic enzymes (CYP11A1, CYP17A1, and others), which drives testosterone synthesis in men and supports the corpus luteum and progesterone in women. Because it stimulates the gonad directly — downstream of the pituitary — it raises intratesticular as well as serum testosterone. HCG is more potent and longer-acting at the receptor than native LH.

The claims

The legitimate, FDA-labeled claims are narrow: prepubertal cryptorchidism not due to anatomical obstruction in boys; selected cases of secondary (pituitary-origin) hypogonadotropic hypogonadism in males; and induction of ovulation in appropriately selected anovulatory infertile women, where it is used as an “ovulation trigger” after FSH pretreatment in assisted reproduction.

The biggest popular claim — weight loss via the “hCG diet” (the Simeons protocol of a very-low-calorie diet plus hCG injections) — is not an approved use and is explicitly disclaimed.

In the fitness world, hCG is used off-label for a different reason. In AAS users, exogenous androgens suppress the hypothalamic-pituitary-testicular axis, shutting down LH/FSH and causing testicular atrophy and impaired spermatogenesis. HCG is used to directly stimulate the testes in an attempt to maintain testicular size/function and intratesticular testosterone, and in “restart” and fertility-recovery contexts. It is also used clinically as an adjunct to testosterone-replacement therapy (TRT) to preserve fertility. Importantly, hCG is not an anabolic or muscle-building agent itself — any effect on muscle is indirect, via the endogenous testosterone it raises, and it does not match the magnitude of exogenous androgen effects.

What the evidence actually shows

Weight loss: no credible evidence. A criteria-based meta-analysis (Lijesen et al., Br J Clin Pharmacol 1995; 24 trials — 8 controlled and 16 uncontrolled) found no scientific evidence that hCG is effective for weight loss, fat redistribution, or reducing appetite/hunger beyond what caloric restriction alone achieves. This is the basis of the FDA disclaimer, which states plainly that “HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY” and that there is no substantial evidence it increases weight loss.

Male hypogonadotropic hypogonadism and fertility: real benefit in the right population. Gonadotropin therapy (hCG, with or without FSH/hMG) induces spermatogenesis in many men with gonadotropin-deficient hypogonadism. In Liu et al. (J Clin Endocrinol Metab 2009), among 75 gonadotropin-deficient men treated, sperm appeared at a median of about 7 months and 38 men achieved paternity. Larger testis volume, prior gonadotropin treatment, and no prior androgen use each independently predicted faster induction of spermatogenesis, and adding FSH/hMG improved outcomes over hCG alone.

TRT-adjunct fertility preservation: supported. Hsieh et al. (J Urol 2013) found that low-dose intramuscular hCG given alongside testosterone-replacement therapy preserved spermatogenesis — no patient became azoospermic and semen parameters remained stable — supporting its use to mitigate TRT-induced infertility.

Lean mass and strength in healthy athletes: not supported. There is no good evidence that hCG itself increases lean body mass or strength in eugonadal athletes. Its physiologic role is to raise endogenous testosterone, and it is not a substitute for the magnitude of effect seen with supraphysiologic androgens. Any framing of hCG as a direct performance or anabolic agent is not supported by the evidence.

Legal and regulatory status

In the United States, hCG is a prescription drug regulated under the Federal Food, Drug, and Cosmetic Act. It is not a controlled substance and is not scheduled under the Anabolic Steroid Control Act. (For context, anabolic steroids are Schedule III controlled substances; clenbuterol is not FDA-approved for humans and not scheduled; and HGH/somatropin has its own statute, 21 U.S. Code § 333(e), criminalizing distribution for non-approved human uses — none of those scheduling regimes covers hCG.)

Selling hCG without a valid prescription, or marketing over-the-counter or “homeopathic” hCG weight-loss drops and pills, is unlawful: FDA and FTC consider these products illegal, fraudulent, unapproved, and misbranded drugs and have issued joint warning letters to firms selling them. Possession and use with a valid prescription, however, are legal.

In sport, hCG (chorionic gonadotrophin, CG), luteinizing hormone (LH), and their releasing factors are prohibited under WADA Category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — in the testosterone-stimulating-peptides subsection — at all times (in- and out-of-competition), and only in male athletes. (For context, anabolic agents fall under S1, with clenbuterol listed among “other anabolic agents,” and growth hormone is also an S2 substance.)

Safety

HCG’s safety profile differs meaningfully from that of AAS, because its core pharmacology is stimulating endogenous testosterone rather than delivering an exogenous androgen. Several classic AAS toxicities are simply not intrinsic to it:

No 17-alpha-alkylated hepatotoxicity — that liver-injury risk applies to oral alkylated steroids, which hCG is not.
It is not a direct HPTA suppressor the way exogenous androgen is; it is in fact used to counter testicular shutdown. That said, by chronically driving testosterone (and aromatization to estradiol), it can still disrupt normal feedback and cause its own form of dysregulation or Leydig-cell desensitization with overuse.

Documented and expected adverse effects include:

Gynecomastia and breast tenderness, via increased testosterone aromatizing to estradiol.
Elevated-testosterone effects: acne, oily skin, mood changes, fluid retention/edema, headache, and irritability; and precocious puberty when used in boys for cryptorchidism (a labeled caution).
Injection-site reactions and hypersensitivity/allergic reactions (relevant for the urinary-derived protein products).
Ovarian hyperstimulation syndrome (OHSS) and multiple gestation when used as an ovulation trigger in women — a recognized, potentially serious risk — and arterial/venous thromboembolism has been reported in the ovulation-induction setting.

Effects tied to raising androgen levels can also appear if testosterone rises substantially: possible adverse lipid changes (lowered HDL), increased hematocrit/erythrocytosis risk, and theoretical cardiovascular strain. These are generally driven by the resulting androgen and estrogen levels rather than by hCG itself, and are less pronounced than with supraphysiologic exogenous AAS. Notably, virilization, HPTA suppression, and infertility are primarily concerns of exogenous androgens — hCG is frequently used precisely because it can help preserve fertility and testicular function rather than suppress it — but misuse through excessive or chronic stimulation can still cause Leydig-cell desensitization and downstream hormonal imbalance. As a general caution, hCG is not for anyone with androgen-sensitive conditions (such as prostate cancer), precocious puberty, or known hypersensitivity, and its use in women carries the OHSS, thrombosis, and multiple-pregnancy risks noted above. None of this is medical advice.

Bottom line

HCG is a glycoprotein gonadotropin that works as an LH analog, not a steroid and not a direct anabolic. The evidence sorts cleanly along the line between its real uses and its hyped ones: there is strong human support for inducing spermatogenesis in gonadotropin-deficient men and for preserving fertility during TRT, and a formal FDA disclaimer — backed by a meta-analysis — against the discredited “hCG diet.” There is no good evidence it builds muscle or strength on its own in healthy people. In the US it is a prescription drug, not a controlled substance, but over-the-counter weight-loss hCG is illegal and fraudulent; in sport it is banned at all times in males.

Evidence grade: Strong human. Strong for its real endocrine indications (fertility, hypogonadism) and for the negative finding on weight loss; not supported as a standalone performance or anabolic agent.

HCG (Human Chorionic Gonadotropin)